OncoMed Pharmaceuticals Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at EORTC-NCI-AACR Meeting

Autor:	OncoMed Pharmaceuticals, Inc.
Zdroj:	Business Wire (English). 11/09/2012.
Abstrakt:	OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced multiple presentations of clinical data on its Anti-Notch2/3 and demcizumab programs at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Phase I clinical data on Anti-Notch2/3 were featured in an oral plenary session and additional clinical biomarker data were presented in a poster session. Demcizumab Phase Ib clinical data in non-small cell lung cancer patients were also featured in a separate poster session. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.